Top Markets
Coin of the day
MaaT Pharma S.A. MaaT Pharma S.A.

MaaT Pharma S.A.

MAAT
주식 순위 #23616
MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on... MaaT Pharma SA operates as a clinical-stage biotechnology company, focused on the discovery and advancement of microbiome-based biotherapies, primarily for the treatment of solid cancer tumors. Its development pipeline features MaaT013, which has successfully completed Phase 2 clinical trials for acute graft-versus-host disease (aGVHD) and is also undergoing preclinical evaluation for melanoma. Another therapeutic candidate, MaaT033, is currently in Phase 1b clinical trials, aiming to improve survival outcomes for patients with acute myeloid leukemia (AML) or other liquid malignancies following allogeneic hematopoietic stem cell transplantation. Furthermore, MaaT03X is being developed specifically for solid tumor applications. The company was founded in 2014 and maintains its headquarters in Lyon, France.
주가
$3.78
마지막 동기화: 2026-08-21
시가총액
$71.20M
변동 (1일)
2.24%
변동 (1년)
-43.37%
국가
FR
거래 MaaT Pharma S.A. (MAAT)

카테고리

MaaT Pharma S.A. (MAAT)의 EPS
2026 기준 EPS TTM: 0
MaaT Pharma S.A.의 최신 재무 보고서와 주가에 따르면, 현재 EPS (TTM)는 0입니다. 2026년 말에는 회사의 EPS가 0였으며, 이는 2026년의 EPS 0와 동일입니다.
MaaT Pharma S.A.의 EPS 기록 (2026 ~ 2026)
매년 말의 EPS
연도 EPS 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 EPS
회사 EPS EPS 차이 국가
$17.32 -
US
$27.74 -
NL
$-7.98 -
US
$-5.29 -
AU
- -
CH